Hepatect Cp (Human Hepatitis B Immunoglobulin)

Hepatect Cp is indicated for passive immunization against hepatitis B virus in specific clinical situations. It is administered under the direction of a healthcare professional to reduce the risk of infection.

• Post‑exposure prophylaxis for individuals with recent hepatitis B exposure.
• Prevention of hepatitis B recurrence in recipients of liver transplants.
• Supplementation of hepatitis B vaccine when rapid protection is needed.
• Use in newborns of hepatitis B‑positive mothers when vaccine response may be insufficient.
• Management of patients with inadequate anti‑HBs titres after vaccination.

The safety profile of Hepatect Cp reflects the typical reactions observed with immunoglobulin preparations administered intravenously. Most adverse events are mild to moderate and resolve without specific treatment. These reactions are generally dose‑related and can be mitigated by appropriate infusion rates and pre‑medication.

Common

• Mild fever or chills shortly after infusion.
• Headache or transient dizziness.
• Localized injection site discomfort or erythema.
• Nausea or mild gastrointestinal upset.
• Transient increase in serum transaminases.

Serious

• Acute allergic reaction, including urticaria or angioedema.
• Anaphylaxis requiring emergency medical intervention.
• Hemolysis or renal impairment in susceptible patients.
• Thromboembolic events in patients with pre‑existing risk factors.
• Severe hypotension or shock unrelated to allergic reaction.

Hepatect Cp should be used only when the benefits outweigh potential risks, and it requires careful assessment before administration.

• Verify hepatitis B serology and vaccination status prior to use.
• Assess for known hypersensitivity to human immunoglobulins or blood products.
• Use caution in patients with renal insufficiency or a history of hemolysis.
• Monitor vital signs and for signs of allergic reaction during and after infusion.
• Adjust infusion rate in individuals with cardiovascular instability.
• Avoid concurrent administration with live vaccines unless medically justified.
• Document lot number and expiration date for traceability.

Because Hepatect Cp is an immunoglobulin product, certain concomitant medications may alter its safety or efficacy profile.

Avoid

• Concurrent use of other hepatitis B immune globulin preparations.
• Administration with known anaphylactogenic agents without appropriate monitoring.
• Simultaneous infusion with high‑dose intravenous immunoglobulin (IVIG) products, which may increase risk of volume overload.
• Concurrent administration of blood products with unknown hepatitis B status.

Use with caution

• Live attenuated vaccines administered within 3 months of Hepatect Cp.
• Anticoagulants, as infusion may affect coagulation parameters.
• Nephrotoxic drugs in patients with pre‑existing renal impairment.
• Immunosuppressive agents, as they may affect the development of active immunity after vaccination.
• Renal dialysis patients, monitoring for potential accumulation of immunoglobulin.